Overcoming Drug Resistance to Systemic Therapy in Breast Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 15 October 2024 | Viewed by 1617
Special Issue Editors
Interests: biochemistry; molecular biology; molecular immunology; cancer; tumor microenvironment; obesity; cancer immunology; cell therapy (CAR-NK and CAR_T cell therapy)
Interests: breast cancer; EMT; obesity; cytokines; inflammation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Breast cancer is the second most common malignancy in women worldwide. The cause of cancer is multifactorial. The early diagnosis and appropriate treatment of cancer can improve the chances of survival. Other methods of early detection include self-examination, clinical breast examination, and imaging tests such as ultrasound and MRI. Breast cancer is a heterogeneous disease that is considered complex, as there is great diversity within tumors. Despite extensive research, the exact etiology of the disease has not yet been elucidated, as the identified genetic and epigenetic interactions cannot explain the cause of breast cancer in most cases. The existing treatment offers a minimal solution to drug resistance. Thus, there must be an unexplored pathway that contributes to the development of breast cancer. Hence, there is a necessity for novel research to discover a more effective therapeutic approach.
This Special Issue will explore the current state of research in the field of drug resistance, including the mechanisms of drug resistance, the development of new drugs and immunotherapies, and the potential for combination therapies. It will also discuss the challenges associated with drug resistance and the strategies that can be used to address them. Finally, the Special Issue will consider the implications of drug resistance for public health and the need for new approaches to combat this growing problem.
Dr. Nethaji Muniraj
Dr. Dimiter B. Avtanski
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- triple negative breast cancer
- breast cancer stem cells
- tumor microenvironment
- drug resistance
- immunotherapy
- hormone therapy
- targeted therapy
- diagnosis and prevention
- bioactive compounds
